Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Visible integration of the adenosine deaminase (ADA) gene into the recipient genome after gene therapy.

Egashira M, Ariga T, Kawamura N, Miyoshi O, Niikawa N, Sakiyama Y.

Am J Med Genet. 1998 Jan 23;75(3):314-7.

PMID:
9475605
2.

In vivo kinetics of transduced cells in peripheral T cell-directed gene therapy: role of CD8+ cells in improved immunological function in an adenosine deaminase (ADA)-SCID patient.

Kawamura N, Ariga T, Ohtsu M, Kobayashi I, Yamada M, Tame A, Furuta H, Okano M, Egashira M, Niikawa N, Kobayashi K, Sakiyama Y.

J Immunol. 1999 Aug 15;163(4):2256-61.

3.

Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency.

Onodera M, Ariga T, Kawamura N, Kobayashi I, Ohtsu M, Yamada M, Tame A, Furuta H, Okano M, Matsumoto S, Kotani H, McGarrity GJ, Blaese RM, Sakiyama Y.

Blood. 1998 Jan 1;91(1):30-6.

4.

[The gene therapy for a patient with ADA deficiency; report of the first gene therapy trial in Japan].

Ariga T, Kawamura N, Sakiyama Y.

Nihon Rinsho. 1997 Jun;55(6):1572-9. Review. Japanese.

PMID:
9200950
5.

Transfer of the ADA gene into human ADA-deficient T lymphocytes reconstitutes specific immune functions.

Ferrari G, Rossini S, Nobili N, Maggioni D, Garofalo A, Giavazzi R, Mavilio F, Bordignon C.

Blood. 1992 Sep 1;80(5):1120-4.

6.

Adenosine deaminase deficiency as the first target disorder in gene therapy.

Onodera M, Sakiyama Y.

Expert Opin Investig Drugs. 2000 Mar;9(3):543-9. Review.

PMID:
11060694
7.

Adenosine deaminase deficiency: clinical expression, molecular basis, and therapy.

Hershfield MS.

Semin Hematol. 1998 Oct;35(4):291-8. Review.

PMID:
9801258
8.

[Gene therapy for adenosine deaminase deficiency].

Sakiyama Y.

Hokkaido Igaku Zasshi. 1996 Jan;71(1):27-32. Review. Japanese.

PMID:
8727372
9.

Gene therapy for adenosine deaminase deficiency.

Aiuti A, Ficara F, Cattaneo F, Bordignon C, Roncarolo MG.

Curr Opin Allergy Clin Immunol. 2003 Dec;3(6):461-6. Review.

PMID:
14612670
10.

Bone marrow gene therapy for adenosine deaminase deficiency.

Kaptein LC, Einerhand MP, Braakman E, Valerio D, van Beusechem VW.

Immunodeficiency. 1993;4(1-4):335-45. Review.

PMID:
7909479
11.

Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning.

Gaspar HB, Bjorkegren E, Parsley K, Gilmour KC, King D, Sinclair J, Zhang F, Giannakopoulos A, Adams S, Fairbanks LD, Gaspar J, Henderson L, Xu-Bayford JH, Davies EG, Veys PA, Kinnon C, Thrasher AJ.

Mol Ther. 2006 Oct;14(4):505-13.

12.
13.
14.

In vivo transduction by intravenous injection of a lentiviral vector expressing human ADA into neonatal ADA gene knockout mice: a novel form of enzyme replacement therapy for ADA deficiency.

Carbonaro DA, Jin X, Petersen D, Wang X, Dorey F, Kil KS, Aldrich M, Blackburn MR, Kellems RE, Kohn DB.

Mol Ther. 2006 Jun;13(6):1110-20.

15.
16.

[Gene therapy for adenosine deaminase deficiency].

Sakiyama Y, Ariga T, Ohtsu M.

Nihon Rinsho. 2005 Mar;63(3):448-52. Review. Japanese.

PMID:
15773344
18.
19.

Molecular basis for paradoxical carriers of adenosine deaminase (ADA) deficiency that show extremely low levels of ADA activity in peripheral blood cells without immunodeficiency.

Ariga T, Oda N, Sanstisteban I, Arredondo-Vega FX, Shioda M, Ueno H, Terada K, Kobayashi K, Hershfield MS, Sakiyama Y.

J Immunol. 2001 Feb 1;166(3):1698-702.

20.

Adenosine deaminase deficiency with mosaicism for a "second-site suppressor" of a splicing mutation: decline in revertant T lymphocytes during enzyme replacement therapy.

Arredondo-Vega FX, Santisteban I, Richard E, Bali P, Koleilat M, Loubser M, Al-Ghonaium A, Al-Helali M, Hershfield MS.

Blood. 2002 Feb 1;99(3):1005-13.

Supplemental Content

Support Center